Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Marc Raaijmakers, Hartmut Döhner, Dimitri Breems, John Byrd, Konstanze Döhner, Jordi Esteve, Bjørn Gjertsen, Patrycja Gradowska, Gerwin A. Huls, Ain Kaare, Heeje Kim, Hitoshi Kiyoi, Mika Kontro, Janusz Krawczyk, Vladimir Lazarevic, Andrea Lenartova, Alice Mims, Jeannine Refos, Christoph Röllig, Anika Schrade, Karolina Sikorska, Alexandre Theocharides, Peter Valk, Adriano Venditti, Jianxiang Wang, Andrew Wei, Agnieszka Wierzbowska, Andrius Zucenka, Lucille Ferrante, Christina Drenberg Guttke, Angélique Langlois, Christina Loefgren, Kathryn Packman, Prathap Nagaraja Shastri, Natasha Schuier, Meena Thayu, Danielle Trancucci, Bob Lowenberg, Lars Bullinger
Institutions: Universität Ulm, Ziekenhuis aan de Stroom, University of Cincinnati, Hospital Clínic de Barcelona, University of Bergen, University Medical Center Groningen, Tartu University Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Nagoya University, Institute for Molecular Medicine Finland, Lund University, Oslo University Hospital, The Ohio State University, Erasmus MC, Technische Universität Dresden, Erasmus MC Cancer Institute, University Hospital Zurich, University of Rome Tor Vergata, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Peter MacCallum Cancer Centre, Copernicus Memorial Hospital, Vilnius University, Johnson & Johnson (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417015692